S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
From -60% Account to Doubling His Money? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Get MarketBeat All Access Free for 30 Days (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
From -60% Account to Doubling His Money? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Get MarketBeat All Access Free for 30 Days (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
From -60% Account to Doubling His Money? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Get MarketBeat All Access Free for 30 Days (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
From -60% Account to Doubling His Money? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Get MarketBeat All Access Free for 30 Days (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Wall Street Veteran: "A New Wave of Crashes Will Rock US Stocks" (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price & News

$8.35
-0.04 (-0.48%)
(As of 06/2/2023 ET)
Compare
Today's Range
$8.30
$8.49
50-Day Range
$7.37
$8.77
52-Week Range
$7.20
$15.43
Volume
2.47 million shs
Average Volume
2.94 million shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

BioCryst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
79.6% Upside
$15.00 Price Target
Short Interest
Bearish
17.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.85
Upright™ Environmental Score
News Sentiment
0.35mentions of BioCryst Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.03) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

620th out of 983 stocks

Biological Products, Except Diagnostic Industry

100th out of 164 stocks


BCRX stock logo

About BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BCRX Stock News Headlines

BioCryst Pharmaceuticals: An Updated View
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Durham pharma takes $300M loan to pay down debt
See More Headlines

BCRX Price History

BCRX Company Calendar

Last Earnings
5/03/2023
Today
6/02/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BCRX
CUSIP
09058V10
Employees
358
Year Founded
1986

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+80.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-247,120,000.00
Pretax Margin
-77.03%

Debt

Sales & Book Value

Annual Sales
$270.83 million
Book Value
($1.74) per share

Miscellaneous

Free Float
179,488,000
Market Cap
$1.57 billion
Optionable
Optionable
Beta
1.98

Social Links


Key Executives

  • Jon P. StonehouseJon P. Stonehouse
    President, Chief Executive Officer & Director
  • Michael L. Jones
    Executive Director-Finance
  • Anthony DoyleAnthony Doyle
    Chief Financial Officer
  • Helen M. Thackray
    Chief Research & Development Officer
  • Ryan Arnold
    Chief Medical Officer













BCRX Stock - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings
or view top-rated stocks.

What is BioCryst Pharmaceuticals' stock price forecast for 2023?

7 equities research analysts have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their BCRX share price forecasts range from $10.00 to $30.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for BCRX
or view top-rated stocks among Wall Street analysts.

How have BCRX shares performed in 2023?

BioCryst Pharmaceuticals' stock was trading at $11.48 at the start of the year. Since then, BCRX shares have decreased by 27.4% and is now trading at $8.33.
View the best growth stocks for 2023 here
.

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BCRX earnings forecast
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The biotechnology company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $71.44 million. The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) EPS.

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?
What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.85%), State Street Corp (6.03%), Avoro Capital Advisors LLC (5.52%), Pictet Asset Management SA (2.97%), Assenagon Asset Management S.A. (2.64%) and Fisher Asset Management LLC (2.26%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends
.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $8.33.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $1.57 billion and generates $270.83 million in revenue each year. The biotechnology company earns $-247,120,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

The company employs 358 workers across the globe.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for the company is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at investorrelations@biocryst.com, or via fax at 919-859-1314.

This page (NASDAQ:BCRX) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -